Wenwen Jiang

Prof. Dr. Wenwen Jiang

School of Pharmacy, Guizhou University, Guizhou, China
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in International Immunopharmacology
Verified
Journal Article
Closed access
QSQi Sun
Qi Sun
LCLing Chen
Ling Chen
MGMengyu Gao
Mengyu Gao
WJWenwen Jiang
Wenwen Jiang
FSFangxian Shao
Fangxian Shao
BYBoyang Yu
Boyang Yu

22 June 2021 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
PDF file
YRYan Ren
Yan Ren
WJWenwen Jiang
Wenwen Jiang
CLChunli Luo
Chunli Luo
XZXiaohan Zhang
Xiaohan Zhang
MHMingjin Huang
Mingjin Huang

1 December 2009 in Thrombosis Research
Verified
Journal Article
Closed access
WJWenwen Jiang
Wenwen Jiang
JKJunping Kou
Junping Kou
ZZZhi Zhang
Zhi Zhang
BYBoyang Yu
Boyang Yu

1 November 2013 in Chinese Journal of Natural Medicines
Verified
Journal Article
Closed access
HYHao-Peng Yang
Hao-Peng Yang
LYLei Yue
Lei Yue
WJWenwen Jiang
Wenwen Jiang
QLQian Liu
Qian Liu
JKJunping Kou
Junping Kou
BYBo-Yang Yu
Bo-Yang Yu

19 September 2023 in Molecules
Verified
Journal Article
Open access
PDF file
SHShasha He
Shasha He
XHXuhua He
Xuhua He
SPShujuan Pan
Shujuan Pan
WJWenwen Jiang
Wenwen Jiang
Chuanxiong rhizoma (CX) has been utilized for centuries as a traditional herb to treat blood stasis syndromes. However, the pharmacological mechanisms are still not completely revealed. This research was aimed at exploring the molecular mechanisms of CX treatment for thrombosis. Network pharmacology was used to predict the potential anti-thrombosis mechanism after correlating the targets of active components with targets of thrombosis. Furthermore, we verified the mechanism of using CX to treat thrombosis via molecular docking and in vitro experiments. Network pharmacology results showed that a total of 18 active ingredients and 65 targets of CX treatment for thrombosis were collected, including 8 core compounds and 6 core targets. We revealed for the first time that tissue factor (TF) had a close relationship with most core targets of CX in the treatment of thrombosis. TF is a primary coagulation factor in physiological hemostasis and pathological thrombosis. Furthermore, core components of CX have strong affinity for core targets and TF according to molecular docking analysis. The in vitro experiments indicated that Ligustilide (LIG), the representative component of CX, could inhibit TF procoagulant activity, TF mRNA and protein over-expression in a dose-dependent manner in EA.hy926 cells through the PI3K/Akt/NF-κB signaling pathway. This work demonstrated that hemostasis or blood coagulation was one of the important biological processes in the treatment of thrombosis with CX, and TF also might be a central target of CX when used for treating thrombosis. The inhibition of TF might be a novel mechanism of CX in the treatment of thrombosis.

1 March 2011 in SLAS Discovery
Verified
Journal Article
Open access
WJWenwen Jiang
Wenwen Jiang
JKJunping Kou
Junping Kou
SYShengtao Yuan
Shengtao Yuan
LSLi Sun
Li Sun
BYBoyang Yu
Boyang Yu
Tissue factor (TF), the primary initiator of the coagulation cascade, plays a critical role in hemostasis and thrombosis, and inhibition of TF activity appears to be an attractive target for the treatment of cardiovascular diseases. However, few selective small-molecule inhibitors of TF are available, and the present assays for measuring TF activity are relatively expensive and complex. The authors present a simple and high-throughput chromogenic assay for screening TF inhibitors based on using commercial human prothrombin complex instead of purified coagulation factors, reducing the dosage, and performing with a one-stage procedure. In the optimized assay, <45 µL cell lysates was incubated with Tris-CaCl2 buffer (pH 7.3) containing human prothrombin complex at 37°C for 15 min in 96-well or 384-well plates. Tris-EDTA buffer (pH 8.4) containing chromogenic substrate Xa was then added and the absorbance measured at 405 nm. This simplified assay was more sensitive or precise than some reported methods for TF procoagulant activities. Two known active compounds (curcumin and simvastatin) inhibiting TF activity were tested by the simplified assay to validate the screening method. Furthermore, berberine and cryptotanshinone suppressed TF activity induced by lipopolysaccharides in human monocytes by this assay and might be promising new TF inhibitors.